Flash Finance

Hemant Surgical Industries Ltd543916Corporate

Medical Equipment & Supplies Latest results: Mar 2026 8 quarters of data
Consolidated Standalone
₹418.10
MCap ₹544 Cr · P/E 30.2
Hemant Surgical Industries Ltd — Stock analysis & AI research Hemant Surgical Industries Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹167 Cr
Sales · Mar 2026
+187.9% YoY
₹16 Cr
Operating Profit · Mar 2026
+166.7% YoY
9.6%
OPM % · Mar 2026
-6.8% YoY
₹13 Cr
Net Profit · Mar 2026
+160.0% YoY
₹9.84
EPS · Mar 2026
+107.6% YoY

📝 Hemant Surgical Industries Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Hemant Surgical Industries Ltd reported revenue of ₹167 crore for the quarter ended March 2026 (Q4 FY26), up 187.9% from ₹58 crore in the same quarter last year.

Net profit rose 160.0% year-on-year to ₹13 crore, from ₹5 crore. Earnings per share (EPS) came in at ₹9.84.

Operating profit stood at ₹16 crore — an operating margin (OPM) of 9.6%, compared with 10.3% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹231 crore with a net profit of ₹18 crore.

Valuation snapshot

At the current price of ₹418.10, 543916 has a market capitalisation of ₹544 crore and a trailing P/E of about 30.2.

Within the Medical Equipment & Supplies industry, it is the 4th-largest of the 13 companies we track by market value.

Shareholding pattern

As of May 2026, promoters held 52.83%, foreign institutional investors (FIIs) 0.14%, domestic institutional investors (DIIs) 19.94%, public shareholders 27.10% of Hemant Surgical Industries Ltd.

Promoter holding slipped from 58.90% to 52.83% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹544 Cr
Current Price ?
₹418.1
P/E ?
30.20above ind
Industry P/E ?
26.90
P/B ?
3.97
P/S ?
2.35
P/FCF ?
-15.99
Enterprise Value ?
₹594 Cr
EV/EBITDA ?
24.73
PEG ?
0.89
Earnings Yield ?
3.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹231 Cr
OPM ?
10.4%
Profit after tax (TTM) ?
₹18 Cr
EPS (TTM) ?
₹13.85
ROCE ?
20.0%
ROE ?
13.1%
ROA ?
6.6%
Growth
Sales — latest qtr ?
₹167 Cr
PAT — latest qtr ?
₹13 Cr
YoY qtr sales growth ?
187.9%
YoY qtr profit growth ?
160.0%
Sales growth (3y) ?
28%
Sales growth (5y) ?
31%
Profit growth (3y) ?
34%
Profit growth (5y) ?
68%
Financial Health
Debt ?
₹50 Cr
Debt to Equity ?
0.36
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.83%
Change in promoter holding ?
-20.73%
Pledged percentage ?
N/A
Market
Return 3 months ?
11.4%
Return 6 months ?
53.9%

🗓️ Quarterly results (8 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 51584858495864167 +187.9% —
Operating Profit 463746816 +166.7% —
Other Income 11322323 +0.0% —
Interest 11101122 +100.0% —
Depreciation 00111111 +0.0% —
Profit Before Tax 465846716 +166.7% —
Net Profit 254635513 +160.0% —
EPS 48.126.933.755.633.054.744.159.84 +107.6% —
OPM % 7.8% 10.3% 6.2% 12.1% 8.2% 10.3% 12.5% 9.6% -6.8% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 8101013 +30.0%
Reserves 164453124 +134.0%
Borrowings 773150 +61.3%
Other Liabilities 34385487 +61.1%
Total Liabilities 65100148274 +85.1%
Fixed Assets 13184053 +32.5%
CWIP 00120 -100.0%
Investments 0510 -100.0%
Other Assets 517794220 +134.0%
Total Assets 65100148274 +85.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 6-49-32 -455.6%
Cash from Investing Activity -3-12-30-3 +90.0%
Cash from Financing Activity -1211869 +283.3%
Net Cash Flow 35-434 +950.0%
Free Cash Flow 2-13-25-34 -36.0%
CFO/OP 84%-9%126%-118% -193.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 587570106 +51.4%
Inventory Days 6799205120 -41.5%
Days Payable 110116188146 -22.3%
Cash Conversion Cycle 15588780 -8.0%
Working Capital Days 2526124 -60.7%
ROCE % 45%30%16%20% +25.0%

👥 Shareholding (latest 4 periods)

Metric Mar 2025Sep 2025Mar 2026May 2026 % Chg
Promoters 73.56%58.90%58.90%52.83% -10.3%
FIIs 0.39%0.15%0.15%0.14% -6.7%
DIIs 1.11%10.81%10.73%19.94% +85.8%
Public 24.93%30.13%30.21%27.10% -10.3%
No. of Shareholders 1,229758841948 +12.7%

⚖️ Peer comparison

Industry: Medical Equipment & Supplies · 13 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 FISCHER Fischer Medical ₹33.50 2,293 85.2 367 24 12.3% 6.7% 178.6% 2051.4% 249.4% -24.3%
2 TARSONS Tarsons Products ₹330.00 1,756 157.9 441 11 27.0% 2.5% -66.3% -81.4% 20.7% -181.0%
3 DENTALKART Vasa Denticity ₹563.10 977 80.0 299 12 4.4% 4.0% 16.7% -28.5% 12.9% -2.9%
4 543916 Hemant Surgical ₹193.85 544 13.9 231 18 10.4% 7.8% — — 187.9% 160.0%
5 543363 Prevest Denpro ₹616.50 456 32.8 75 23 35.7% 29.9% 13.6% 17.6% 23.7% 24.8%
6 QMSMEDI QMS Medical ₹185.89 359 52.7 162 7 13.1% 4.1% 5.1% -47.9% 23.7% -0.8%
7 NURECA Nureca ₹331.55 331 75.9 153 4 2.7% 2.8% 34.0% 146.7% 18.0% 277.2%
8 530427 Choksi Asia ₹65.64 122 7.2 47 5 14.5% 11.1% 61.1% 173.2% -22.5% -10.1%
9 527005 Shree Pacetronix ₹168.25 55 19.2 21 3 24.8% 15.3% 28.7% 324.3% -8.3% 14.5%
10 544143 Royal Sense ₹139.00 47 24.7 38 3 12.8% 8.0% — — 2.5% -5.4%
11 533212 GKB Ophthalmics ₹104.90 32 17.6 150 6 7.0% 3.7% 36.8% 142.7% 2.3% 388.5%
12 531380 Centenial Surgical ₹110.90 27 — 56 -1 10.7% -2.6% 0.6% -38.1% 18.6% 1937.8%
13 542765 Transpact Enterprises ₹325.00 4 140.1 0 0 63.2% 47.4% — — 12.5% -20.0%
❓ Frequently asked questions
What was Hemant Surgical Industries Ltd's revenue in Q4 FY26?
Hemant Surgical Industries Ltd reported revenue of ₹167 crore for the quarter ended March 2026 (Q4 FY26), up 187.9% from ₹58 crore in the same quarter last year.
What was Hemant Surgical Industries Ltd's net profit in Q4 FY26?
Net profit rose 160.0% year-on-year to ₹13 crore, from ₹5 crore. Earnings per share (EPS) came in at ₹9.84.
What is 543916's market capitalisation and P/E ratio?
At the current price of ₹418.10, 543916 has a market capitalisation of ₹544 crore and a trailing P/E of about 30.2.
Who owns Hemant Surgical Industries Ltd? (shareholding pattern)
As of May 2026, promoters held 52.83%, foreign institutional investors (FIIs) 0.14%, domestic institutional investors (DIIs) 19.94%, public shareholders 27.10% of Hemant Surgical Industries Ltd.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI